UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Brain Metastases Clinical Trial

Official title:

A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05535413
• Other study ID #: HNCH-2022KY59
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: August 1, 2022
• Est. completion date: July 2025

Study information

• Verified date: September 2022
• Source: Hunan Cancer Hospital
• Contact: Quchang Ouyang
• Phone: +8673189762161
• Email: oyqc1969[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: July 2025
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients aged 18 to 70 years

• With histologically confirmed HER2 negative recurrent and metastatic breast cancer

• have at least one measurable lesion in the central nervous system (the longest diameter = 10mm)

• ECOG score (PS) of 0-2

• According to screening brain MRI, patients with CNS must meet the following conditions:

1. untreated brain metastases of breast cancer;

2. do not need immediate local treatment;

3. brain metastases of breast cancer which was treated in the past:

1. There are no clinical manifestations that have progressed after the previous local treatment of the central nervous system and require immediate local treatment.

2. All records related to the treatment of the central nervous system must be provided.

3. All toxicities related to the previous anti-tumor treatment of patients who have not received chemotherapy, radiotherapy, surgical treatment, targeted therapy and immunotherapy within 4 weeks before enrollment must be restored to = level 1 (CTCAE v50). However, patients with hair loss of any grade are allowed to be recruited.

• Blood routine examination was basically normal within 1 week before enrollment.

• White blood cell count (WBC) = 30 × 109 /L

• Neutrophil counts (ANC) = 15 × 109/L

• Platelet count (PLT) = 100 × 109 /L

• Hemoglobin = 90g/dl. Patients can receive blood transfusion or erythropoietin treatment to meet this standard.

• Within 1 week before enrollment, the liver and kidney function tests were basically normal (based on the normal value of the laboratory of each research center).

• Total bilirubin = 15 × Upper limit of normal value (ULN)

• Alanine aminotransferase (SGPT / ALT) = 25 x ULN (patients with liver metastasis = 5 × ULN)

• Glutamic oxaloacetic transaminase (SGOT/AST) = 25 × ULN (patients with liver metastasis = 5 × ULN)

• Creatinine clearance rate (Ccr) = 60ml/min patients

• With fertility must agree to use effective contraceptive methods during the study period and within 90 days of the last study medication. Before enrollment, the blood or urine pregnancy test must be negative and the

• Life expectancy > 12 weeks.

• The patient must be able to participate in and follow the treatment and follow-up.

Exclusion Criteria:

• Primary or metastatic lesions were HER2 positive (HER2 IHC or FISH positive)

• Other malignant carcinomas (including primary brain or leptomeningeal related tumors) in the past 5 years, except for the cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.

• Anti tumor treatment, including chemotherapeutic radical radiotherapy, hormone therapy, biological therapy Immunotherapy or anti-tumor traditional Chinese medicine.

• Patients who have received surgical operation on major organs (excluding puncture biopsy) or have suffered significant trauma within 4 weeks before the first use of the study drug, or who need to undergo elective surgery during the trial.

• Patients with symptomatic peripheral neuropathy with grade evaluation = 2 (CTCAE 5.0), who have previously used anti-microtubule drugs and have serious adverse reactions related to the nervous system of grade 3 or above.

• Use capecitabine within 6 months before enrollment; No response to capecitabine in the past (including progression during capecitabine treatment, or duration of clinical response after treatment < 3 months) or unable to tolerate to capecitabine.

• For any brain lesions requiring immediate local treatment, such as increased lesion size or treatment-related edema at intracranial (but not limited to) anatomical sites may pose risks to patients (e.g., brainstem lesions)

• Known or suspected leptomeningeal disease (LMD)

• Other non malignant systemic diseases (cardiovascular, renal, liver, etc.) that are excluded from any treatment regimen or interfere with follow-up in pregnant or lactating women.

• Known or suspected allergy to any study drug or accessories.

• Brain MRI can not be performed for any other reason.

• The investigator considers it inappropriate to participate in.

• Other situations where corticosteroids are prohibited.

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• Breast Neoplasms
• Capecitabine
• Metastatic HER2 Negative Breast Carcinoma
• Neoplasm Metastasis

Intervention

Drug:
• UTD1 combined with capecitabine
UTD1: 30mg/m2/day, once a day, continuously from day 1 to day 5, 21 days as a treatment cycle. Capecitabine: 2000mg / m2 / day, continuously from day 1 to day 14, orally twice a day, 21 days as a treatment cycle.

Locations

Country	Name	City	State
China	Quchang Ouyang	Changsha

Sponsors (1)

Lead Sponsor	Collaborator
Hunan Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CNS-Objective Response Rate (ORR)	The proportion of patients with complete remission (CR) and partial remission (PR) as the best efficacy evaluation in the total number of evaluable patients observed during the process from enrollment to the progression of all CNS target lesions assessed according to the RANOBM criteria.	From the enrollment to the progression of all CNS target lesions assessed according to RANOBM standard up to 1 year.
Secondary	CNS clinical benefit rate (CNS-CBR)	The percentage of patients who achieved complete response (CR), partial response (PR) or disease stability (SD) as the best efficacy evaluation in the total number of evaluable patients observed from enrollment to all CNS target lesions assessed according to the RANOBM criteria.	From the enrollment to the progression of all CNS target lesions assessed according to RANOBM standard up to 1 year.
Secondary	CNS progression free survival (CNS-PFS)	The time from enrollment to the first imaging confirmed disease progression (PD) of all central nervous system target lesions (RANOBM criteria) or death due to any cause without progression recorded.	From enrollment to the first imaging confirmed disease progression (PD) of all central nervous system target lesions (RANOBM criteria) or death due to any cause without progression recorded up to 1 year.
Secondary	CNS objective response rate (CNS-ORR)	The proportion of patients with complete remission (CR) and partial remission (PR) as the best efficacy evaluation in the total number of evaluable patients observed during the process from enrollment to the progression of all CNS target lesions assessed according to the RECIST 1.1 criteria.	From the enrollment to the progression of all CNS target lesions assessed according to RECIST 1.1 standard up to 1 year.
Secondary	Objective response rate (ORR)	According to RECIST 1.1 criteria, the number of patients with the best efficacy evaluation of CR or PR during the process from enrollment to disease progression accounts for the proportion of the total number of evaluable patients.	From the enrollment to the progression of all CNS target lesions assessed according to RECIST standard up to 1 year.
Secondary	Progressive survival (PFS)	The time from enrollment and disease progression (PD) confirmed by imaging from enrollment to the first time (RECIST 1.1 criteria) or death without progress is recorded but due to any cause.	From the enrollment to the progression of all CNS target lesions assessed according to RECIST standard up to 1 year.